The ruling by a Missouri state court jury is a rare legal win for Abbott Laboratories, maker of Similac formula, and Reckitt, ...

The Whitfield family legal case was just one of many still pending relating to the necrotizing enterocolitis (NEC) disease.

Harvey Jones rejected any thought of buying this former FTSE 100 darling in August but after some positive news should he now revise his opinion? The post After jumping 10% this morning is this hated ...

"The decision reinforces what we, the medical community and regulatory bodies have said: that preterm infant nutrition products are safe," Abbott said in a statement. Mead Johnson said the verdict ...

Abbott Laboratories and a unit of Reckitt Benckiser Group were cleared by a jury over claims they hid risks in their premature-infant formulas can cause a bowel disease that severely sickened a baby ...

In response, shares in Reckitt Benckiser soared 9.8% to 5,144.20 pence each in London early Friday. Reckitt was the best performing stock in the FTSE 100 index which was up 0.2%. Abbott Laboratories ...

was cleared of liability in a preterm formula case. "This feels like a big deal to us, putting a spoke in the wheels of what has hitherto been an unremittingly adverse narrative," said RBC ...

LONDON (Reuters) - Shares in British consumer goods company Reckitt Benckiser jumped over 10% on Friday after the company, along with U.S.-based Abbott Labs, was cleared of liability in a preterm ...

Shares of Abbott, which makes the Similac formula, rose 5.4% to $ ... in compensation related to the death of a premature baby that was fed its Enfamil Premature 24 product. Nearly 1,000 such ...

The decision marks the first victory for the companies as they face more than 1,000 similar cases and previously lost trials, one of which ended with a $500 million verdict.

A jury found Abbott Laboratories and Mead Johnson, owned by U.K.-based Reckitt Benckiser, not responsible for a young boy's intestinal disease, the result of a lawsuit that alleged the companies ...